𝔽𝔻𝔸 𝔸𝕡𝕡𝕣𝕠𝕧𝕖𝕤 𝕒𝕟𝕕 𝔸𝕦𝕥𝕙𝕠𝕣𝕚𝕫𝕖𝕤 𝕌𝕡𝕕𝕒𝕥𝕖𝕕 𝕞ℝℕ𝔸 ℂ𝕆𝕍𝕀𝔻-𝟙𝟡 𝕍𝕒𝕔𝕔𝕚𝕟𝕖𝕤 𝕥𝕠 𝔹𝕖𝕥𝕥𝕖𝕣 ℙ𝕣𝕠𝕥𝕖𝕔𝕥 𝔸𝕘𝕒𝕚𝕟𝕤𝕥 ℂ𝕦𝕣𝕣𝕖𝕟𝕥𝕝𝕪 ℂ𝕚𝕣𝕔𝕦𝕝𝕒𝕥𝕚𝕟𝕘 𝕍𝕒𝕣𝕚𝕒𝕟𝕥𝕤

Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.

The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc.

Today, we approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. https://t.co/pul33IEnIw

The mRNA COVID-19 vaccines have… pic.twitter.com/HkZlPX8jwW

— U.S. FDA (@US_FDA) August 22, 2024

We need more Dr’s like this 👏

Dr. Hodkinson: "It's Not a Time to Say 'I'm Sorry' – It's a Time to Put These Bastards in Jail"

"Should we forgive and forget?" "Absolutely not!" roared Dr. Roger Hodkinson. pic.twitter.com/330iGkecfx

— Raymond (@Raymond82310289) April 7, 2024

Global excess deaths

Source